Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,876 | -8,214 | -3,094 | -2,466 | -1,986 |
| Depreciation Amortization | 35 | 35 | 38 | 27 | 17 |
| Accounts payable and accrued liabilities | -24 | 98 | -174 | 716 | 405 |
| Other Working Capital | 30 | 109 | -324 | 1,016 | 517 |
| Other Operating Activity | 8,722 | 6,919 | 223 | -480 | -41 |
| Operating Cash Flow | $-2,113 | $-1,053 | $-3,331 | $-1,188 | $-1,088 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | -1 | -20 | N/A | N/A |
| Investing Cash Flow | $-4 | $-1 | $-20 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 400 | 400 | 500 | N/A | N/A |
| Common Stock Issued | 3,332 | 3,340 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 0 | 3,013 | 1,132 | 1,132 |
| Financing Cash Flow | $3,732 | $3,740 | $3,513 | $1,132 | $1,132 |
| Beginning Cash Position | 264 | 264 | 102 | 102 | 102 |
| End Cash Position | 1,879 | 2,950 | 264 | 46 | 146 |
| Net Cash Flow | $1,615 | $2,685 | $162 | $-56 | $44 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,113 | -1,053 | -3,331 | -1,188 | -1,088 |
| Capital Expenditure | -4 | -1 | -20 | N/A | N/A |
| Free Cash Flow | -2,117 | -1,054 | -3,351 | -1,188 | -1,088 |